Net Cash Provided by (Used in) Financing Activities of AYTU BIOPHARMA, INC from 30 Nov 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
AYTU BIOPHARMA, INC quarterly and annual Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 30 Nov 2010 to 30 Sep 2025.
  • AYTU BIOPHARMA, INC Net Cash Provided by (Used in) Financing Activities for the quarter ending 30 Sep 2025 was $2,296,000, a 152% increase year-over-year.
  • AYTU BIOPHARMA, INC annual Net Cash Provided by (Used in) Financing Activities for 2025 was $15,443,000.
  • AYTU BIOPHARMA, INC annual Net Cash Provided by (Used in) Financing Activities for 2024 was $1,262,000, a 114% decline from 2023.
  • AYTU BIOPHARMA, INC annual Net Cash Provided by (Used in) Financing Activities for 2023 was $8,871,000, a 480% increase from 2022.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

AYTU BIOPHARMA, INC Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,296,000 +$1,385,000 +152% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2026 Q1
Q3 2024 $911,000 +$3,645,000 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2026 Q1
Q3 2023 $2,734,000 -$16,291,000 -120% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2023 2024 Q1
Q3 2022 $13,557,000 +$19,021,000 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2024 Q1
Q3 2021 $5,464,000 -$3,286,000 -151% 01 Jul 2021 30 Sep 2021 10-Q/A 21 Feb 2023 2023 Q1
Q3 2020 $2,178,000 -$2,178,000 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2022 Q1
Q3 2019 $0 $0 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2021 Q1
Q3 2018 $0 -$10,437,164 -100% 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019 2020 Q1
Q3 2017 $10,437,164 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018 2019 Q1
Q4 2014 $16,008 +$10,567 +194% 01 Sep 2014 30 Nov 2014 10-Q 12 Jan 2015 2015 Q1
Q4 2013 $5,441 -$4,067 -43% 01 Sep 2013 30 Nov 2013 10-Q 12 Jan 2015 2015 Q1
Q4 2012 $9,508 +$773 +8.8% 01 Sep 2012 30 Nov 2012 10-Q 10 Jan 2014 2014 Q1
Q4 2011 $8,735 -$2,514 -22% 01 Sep 2011 30 Nov 2011 10-Q 14 Jan 2013 2013 Q1
Q4 2010 $11,249 01 Sep 2010 30 Nov 2010 10-Q 23 Dec 2011 2012 Q1

AYTU BIOPHARMA, INC Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $15,443,000 +$16,705,000 01 Jul 2024 30 Jun 2025 10-K 23 Sep 2025 2025 FY
2024 $1,262,000 -$10,133,000 -114% 01 Jul 2023 30 Jun 2024 10-K 23 Sep 2025 2025 FY
2023 $8,871,000 +$7,341,000 +480% 01 Jul 2022 30 Jun 2023 10-K 26 Sep 2024 2024 FY
2022 $1,530,000 -$28,784,000 -95% 01 Jul 2021 30 Jun 2022 10-K 12 Oct 2023 2023 FY
2021 $30,314,000 -$40,755,000 -57% 01 Jul 2020 30 Jun 2021 10-K 27 Sep 2022 2022 FY
2020 $71,069,000 +$51,993,938 +273% 01 Jul 2019 30 Jun 2020 10-K 28 Sep 2021 2021 FY
2019 $19,075,062 -$3,584,537 -16% 01 Jul 2018 30 Jun 2019 10-K 06 Oct 2020 2020 FY
2018 $22,659,599 +$12,472,057 +122% 01 Jul 2017 30 Jun 2018 10-K 26 Sep 2019 2020 FY
2017 $10,187,542 01 Jul 2016 30 Jun 2017 10-K 06 Sep 2018 2018 FY
2013 $39,457 +$5,492 +16% 01 Sep 2012 31 Aug 2013 10-K 26 Nov 2014 2013 FY
2012 $33,965 -$33,301 -50% 01 Sep 2011 31 Aug 2012 10-K 26 Nov 2014 2013 FY
2011 $67,266 01 Sep 2010 31 Aug 2011 10-K 29 Nov 2012 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.